Hugel (145020) Fundamentals 2026 — P/E 16.8x, Revenue Analysis | SniperIQ
Hugel (145020) is a KR-listed Healthcare company in Biotechnology with a market capitalization of ₩2.39T, trading at ₩221500.00 on the KOE. This SniperIQ fundamentals page covers Hugel's valuation (P/E 16.8x, P/B 2.8x), profitability (net margin 33.4%), revenue (₩425.1B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Hugel's market cap?
Hugel (145020) has a market capitalization of approximately ₩2.39T, trading at ₩221500.00 on the KOE. Market cap moves with the live share price.
What is Hugel's P/E ratio?
Hugel's trailing twelve-month P/E ratio is 16.8x, with a price-to-book (P/B) of 2.8x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Hugel?
Hugel runs a net profit margin of 33.4%, a gross margin of 77.3%, and an operating margin of 46.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Hugel generate?
Hugel reported revenue of ₩425.1B for fiscal year 2025, with net income of ₩140.9B and earnings per share (EPS) of 13061. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Hugel pay a dividend?
Hugel does not currently show a material trailing dividend yield; it is positioned more as a total-return name. Always confirm the latest dividend policy in the company's filings.
Is Hugel financially healthy?
Hugel carries a debt-to-equity ratio of 0.03x and a current ratio of 7.49x, with a market beta of 0.49. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Hugel a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Hugel (145020) the key facts are: market cap ₩2.39T, P/E 16.8x, revenue ₩425.1B, 52-week range 208500-369000. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Hugel's full fundamentals live
Get Hugel's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.